Replimune Group, Inc. REPL

Replimune Group reported fiscal first quarter 2027 financial results and issued a corporate update. Quarterly results and updates typically deliver moderate effects on near-term market views without altering long-term trajectory.

Replimune Group (REPL) secures FDA approval for its advanced melanoma treatment. FDA approval for melanoma treatment positions Replimune for major growth in oncology market.

Replimune Group’s drug shows potential to treat hot flashes, driving a 36% increase in the company’s stock price. New indication for the drug expands addressable market and triggers sharp positive revaluation of Replimune shares.

Replimune Group (REPL) stock nears 18-month high after pricing $150M offering, though retail investors expect share price to unwind over time. $150M offering supplies fresh capital but signals dilution that can pressure stock trajectory.

Replimune launches first commercial drug while facing 2027 cash cliff and 2030 target milestones. First commercial drug marks major strategic advance that can reshape revenue path and investor views despite cash pressures.

Replimune Group secured FDA approval for its skin cancer drug after three attempts, but shares fell in response. FDA drug approval marks a pivotal regulatory success with potential to reshape company trajectory despite immediate share decline.

Replimune receives FDA accelerated approval for TUDRIQEVTM in combination with nivolumab to treat unresectable advanced cutaneous melanoma after progression on anti-PD-1 regimens. FDA accelerated approval grants Replimune immediate commercial access to a major oncology indication and validates its lead asset.

Replimune Group shares fell 11% in after-hours trading amid investor selloff. 11% after-hours drop signals short-term negative sentiment without altering long-term company trajectory.

Replimune Group awaits pending FDA decision on melanoma treatment, with analyst citing 40% stock upside and high conviction in approval. Pending FDA melanoma decision represents regulatory ruling with potential to fundamentally redefine Replimune's competitive position.

Replimune Group shares rose 15.5% after FDA panel backing for RP1 data, with further regulatory and development steps ahead. FDA panel support for RP1 marks major regulatory progress that can shift company trajectory and investor sentiment.

Replimune Group stock surges 107% after FDA advisory panel votes in favor of its skin cancer treatment. FDA panel support for skin cancer therapy can secure approval and transform Replimune's market position.

Replimune stock surges 132% after positive FDA panel vote on its skin cancer treatment. Positive FDA panel vote on lead skin cancer therapy triggers 132% stock surge and signals likely approval with major long-term impact.

Replimune Group stock hit its best day on record after an analyst increased the odds of approval for its melanoma therapy due to an overwhelmingly positive advisory panel outcome. Higher melanoma approval odds represent major regulatory progress on a core product that can materially shift Replimune's trajectory and investor sentiment.

Replimune Group shares surged 127% in after-hours trading on undisclosed positive developments. Extreme 127% stock surge signals a major catalyst with potential to redefine company prospects.

Replimune announces favorable FDA Cellular, Tissue, and Gene Therapies Advisory Committee outcome for RP1 in advanced melanoma. Favorable FDA advisory outcome for lead candidate RP1 advances regulatory path and commercialization prospects in melanoma.

FDA documents signal likely rejection for Replimune's cancer drug, triggering REPL stock's worst day in over 3 months. Potential FDA rejection for core cancer drug threatens approval timeline, valuation, and future performance.

Replimune Group faces an ongoing regulatory standoff that directly affects its stock performance and outlook. Regulatory standoff creates major risks for Replimune's approvals and market trajectory.

FDA reviewers question RP1 efficacy for melanoma, triggering fall in Replimune shares. FDA doubts on lead drug RP1 threaten approval chances and long-term revenue outlook.

FDA staff raised concerns over Replimune’s skin cancer drug, triggering a 32% crash in REPL stock prior to this week's advisory meeting. FDA concerns on lead drug candidate threaten approval prospects and company valuation.

Replimune Group reported fiscal fourth quarter and year-end 2026 financial results along with a corporate update. Quarterly financial results and corporate updates typically drive short-term stock moves but rarely alter long-term biotech trajectory without clinical data.

Replimune Group announced FDA acceptance of its RP1 Biologics License Application resubmission for advanced melanoma. FDA acceptance of RP1 BLA resubmission advances Replimune toward potential approval and commercialization in advanced melanoma.

Replimune Group plans BLA resubmission for its melanoma combination drug, triggering a sharp surge in REPL shares. BLA resubmission plans for the core melanoma therapy signal major upcoming regulatory milestones that can materially shift company valuation and trajectory.

Replimune Group shares rise sharply in pre-market trading on positive company developments. Pre-market stock gains signal short-term positive sentiment without evidence of fundamental long-term shifts.

Replimune presented final first-in-human data for RP2 in advanced solid tumors during an oral session at the 2026 American Society of Clinical Oncology Annual Meeting. Oral presentation of final first-in-human oncology data at ASCO advances pipeline visibility and development trajectory.

Replimune presented 3-year landmark overall survival analysis from IGNYTE clinical trial during oral presentation at 2026 American Society of Clinical Oncology Annual Meeting. Landmark clinical trial survival data presented at major oncology conference signals strong efficacy that can drive major shifts in valuation and development trajectory.

Replimune Group stock surged 80% on FDA-related developments. Positive FDA regulatory news can materially shift Replimune's approval timeline and valuation trajectory.

Replimune plans to resubmit its melanoma therapy application to the FDA for approval. Resubmission of core melanoma therapy application to FDA represents major regulatory step likely to alter approval prospects and investor sentiment.

Replimune Group plans RP1 BLA resubmission after productive FDA discussions. FDA alignment on RP1 BLA resubmission marks major regulatory progress with direct effects on approval timeline and valuation.

Jefferies highlights reduced visibility for Replimune Group, Inc. (REPL) following an FDA decision. FDA decision prompts Jefferies' view of reduced visibility, indicating significant regulatory impact on REPL's future and market performance.

Replimune Group (REPL) stock plummeted 75% after the FDA rejected its Biologics License Application (BLA) for RP1 in melanoma due to concerns over the trial design. FDA rejection of RP1 BLA over trial design flaws triggered a 75% stock drop, profoundly damaging Replimune's melanoma treatment prospects and long-term market position.